



Caplacizumab

Targets (1)

This drug entry is a **stub** and has not been fully annotated. It is scheduled to be annotated soon.

IDENTIFICATION

Name

Caplacizumab

Accession Number

DB06081

Type

Small Molecule

Groups

Investigational

Description

ALX-0081 is a novel 'first-in-class' therapeutic Nanobody® targeting von Willebrand Factor (vWF), which can reduce the risk of thrombosis in patients with acute coronary syndrome. ALX-0081 is intended to prevent arterial thrombosis, without interfering with the desired haemostatis (wound healing) in the patient which results in less bleeding complications.

Synonyms

Not Available



[Amino Acid Sequence](#)

[Amino Acids, Peptides, and Proteins](#)

[Biochemical Phenomena](#)

[Blood Proteins](#)

[Globulins](#)

[Immunoglobulin Fab Fragments](#)

[Immunoglobulin Fragments](#)

[Immunoglobulin Variable Region](#)

[Immunoglobulins](#)

[Immunoproteins](#)

[Information Science](#)

[Information Services](#)

[Molecular Sequence Data](#)

[Molecular Structure](#)

[Peptide Fragments](#)

[Peptides](#)

[Physicochemical Phenomena](#)

[Proteins](#)

[Serum Globulins](#)

[von Willebrand Factor, antagonists & inhibitors](#)

UNII

[2R27AB6766](#)

CAS number

915810-67-2

**Chemical Formula**

Not Available

InChI Key

Not Available

InChI

Not Available

IUPAC Name

Not Available

SMILES

Not Available

PHARMACOLOGY**Indication**

Investigated for use/treatment in cardiovascular disorders and thrombosis.

Pharmacodynamics

ALX-0081 is intended to prevent arterial thrombosis, without interfering with the desired haemostatis (wound healing) in the patient which results in less bleeding complications.

Mechanism of action

ALX-0081 is a Nanobody® targeted against von Willebrand Factor (vWF), a protein found in the blood, that acts at a very early stage in the coagulation cascade, namely platelet adhesion, in contrast to currently available anti-platelet drugs which work only in the late stage of platelet aggregation. The addition of ALX-0081 to the range of tools currently employed in an anti-thrombotic regimen may, therefore, have the potential to improve the overall efficacy of anti-platelet aggregation therapy and lead to an increased use of anti-thrombotic treatment in clinical indications like ACS where there is a high need for immediate and safe therapy.



Human

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Not Available

Route of elimination

Not Available

Half life

Not Available

Clearance

Not Available

Toxicity

Not Available

Affected organisms

Not Available

Pathways

Not Available



INTERACTIONS

Drug Interactions ⓘ

ALL DRUGS

APPROVED

VET APPROVED

NUTRACEUTICAL

ILLICIT



WITHDRAWN

INVESTIGATIONAL


EXPERIMENTAL

Search

DRUG	↕	INTERACTION	↕
Abciximab		The risk or severity of adverse effects can be increased when Abciximab is combined with Caplacizumab.	
Abituzumab		The risk or severity of adverse effects can be increased when Caplacizumab is combined with Abituzumab.	
Adalimumab		The risk or severity of adverse effects can be increased when Adalimumab is combined with Caplacizumab.	
Adecatumumab		The risk or severity of adverse effects can be increased when Adecatumumab is combined with Caplacizumab.	
Aducanumab		The risk or severity of adverse effects can be increased when Caplacizumab is combined with Aducanumab.	
Afelimomab		The risk or severity of adverse effects can be increased when Afelimomab is combined with Caplacizumab.	
Alemtuzumab		The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Caplacizumab.	
Alirocumab		The risk or severity of adverse effects can be increased when Caplacizumab is combined with Alirocumab.	
Amatuximab		The risk or severity of adverse effects can be increased when Caplacizumab is combined with Amatuximab.	
AMG 108		The risk or severity of adverse effects can be increased when AMG 108 is combined with Caplacizumab.	

Showing 1 to 10 of 237 entries





REFERENCES

General References

Not Available

External Links

Wikipedia

[Caplacizumab](#)

CLINICAL TRIALS

Clinical Trials ⓘ

Search

PHASE	STATUS	PURPOSE	CONDITIONS	COUNT
1	Completed	Treatment	Healthy Volunteers	1
2	Completed	Treatment	Non ST Segment Elevation Myocardial Infarction (NSTEMI) / Stable Angina (Associated With High Risk PCI) / Unstable Angina (UA)	1
3	Active Not Recruiting	Treatment	Acquired Thrombotic Thrombocytopenic Purpura	1
3	Completed	Treatment	Acquired Thrombotic Thrombocytopenic Purpura	1

Showing 1 to 4 of 4 entries

< >

PHARMACOECONOMICS

Manufacturers

Not Available



Not Available

Prices

Not Available

Patents

Not Available

PROPERTIES

State

Solid

Experimental Properties

Not Available

Predicted Properties

Not Available

Predicted ADMET features

Not Available

SPECTRA

Mass Spec (NIST)

Not Available

Spectra

Not Available

TAXONOMY



TARGETS

1. von Willebrand factor**Kind**

Protein

Organism

Human

Pharmacological action

Unknown

General Function

Protein n-terminus binding

Specific Function

Important in the maintenance of hemostasis, it promotes adhesion of platelets to the sites of vascular injury by forming a molecular bridge between sub-endothelial collagen matrix and platelet-surf...

Gene Name

VWF

Uniprot ID[P04275](#)**Uniprot Name**

von Willebrand factor

Molecular Weight

309261.83 Da



[DrugBank Blog](#)

[Wishart Research Group](#)

[Terms of Use](#)

[Privacy Policy](#)

Support

[FAQ](#)

[Help](#)

[Email Support](#)

Commercial Products

[API Pricing](#)

[API Docs](#)

[Data Licenses](#)

[Support](#)



This project is supported by the **Canadian Institutes of Health Research** (award #111062), **Alberta Innovates - Health Solutions**, and by **The Metabolomics Innovation Centre (TMIC)**, a nationally-funded research and core facility that supports a wide range of cutting-edge metabolomic studies. TMIC is funded by **Genome Alberta**, **Genome British Columbia**, and **Genome Canada**, a not-for-profit organization that is leading Canada's national genomics strategy with funding from the federal government. Maintenance, support, and commercial licensing is provided by **OMx Personal Health Analytics, Inc.** Designed by **Educe Design & Innovation Inc.**

